Indeed, a breast cancer PRS was nominally associated with subclonal TP53 mutations (OR = 1.22 per PRS SD, p = 0.03) after restricting to mutation carriers and controlling for tumor purity, indicating that high-PRS individuals that developed TP53 mutations generally did so later or in subclonal populations. This evidence concerns the gene TP53 and neoplasm.